Sage Therapeutics, Inc.
COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS
Last updated:
Abstract:
Provided herein is a compound of Formula (I) ##STR00001## or a pharmaceutically acceptable salt thereof, wherein R.sup.3a, R.sup.5, R.sup.6a, R.sup.6b, R.sup.17, R.sup.21a, R.sup.21b, R.sup.m, R.sup.n, R.sup.16a, R.sup.16b, R.sup.7a, R.sup.7b, R.sup.12a, R.sup.12b, R.sup.11a, R.sup.11b, R.sup.2a, R.sup.2b, R.sup.19, R.sup.4a, and R.sup.4b are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compounds, e.g., in the treatment of CNS-related disorders.
Status:
Application
Type:
Utility
Filling date:
8 Dec 2021
Issue date:
31 Mar 2022